BillionToOne reported Q1 2026 revenue of $108.4 million, up 84% year over year, citing growth across prenatal clinical testing and related services. The company said it accessioned 189,000 tests in Q1 and expects continued momentum as its Unity Confirm test scales. Unity Confirm is a circulating fetal cell-based, non-invasive assay designed to confirm high-risk screening results without using invasive follow-up procedures like CVS or amniocentesis. Management said less than 1% of patients will need follow-up testing, but it expects Unity Confirm to increase uptake of its Unity Aneuploidy screening platform. BillionToOne also said it is enrolling patients for a prospective clinical trial comparing Unity Confirm primarily to CVS, with enrollment expected to take one to three years. The company raised its full-year 2026 guidance to $450 million to $465 million, representing 50% growth at the midpoint.